Breast Cancer - Therapeutic And Competitive Insights

Table of Contents

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 Table of Contents

• 4.1 Boxes
• 4.2 Tables

5 Introduction

• 5.1 Disease Definitions
• 5.2 Etiology
• 5.3 Epidemiology
• 5.4 Prognosis

6 Current Treatment Strategies

• 6.1 Localized Disease
• 6.2 Advanced Disease

7 Progress in Current Treatment Strategies

• 7.1 Hormone Based Therapies
• 7.2 Antibodies
• 7.3 Chemotherapy

8 Key Therapeutic Strategies for Future Therapies

• 8.1 Therapeutic Type, Targets & Mechanisms

9 Competitive Landscape in Drug Development: The Late Stage Pipeline

• 9.1 The Epothilones
• 9.2 Cell Cycle & Apoptosis
• 9.3 Protein Kinase Inhibitors
• 9.4 Immunotherapy

10 Current Drug Development: The Early Stage Pipeline

• 10.1 DNA Targeting
• 10.2 FTIs
• 10.3 Antisense
• 10.4 New Hormone Modulators
• 10.5 Other

11 Drug Index

12 Company Index

13 Disclaimer

• 13.1 Liability
• 13.2 Completeness

List of Boxes

• Box 1: Ongoing Phase III Studies Anastrozole
• Box 2: Ongoing Phase III Studies Letrozole
• Box 3: Ongoing Phase III Studies Exemestane
• Box 4: Ongoing Phase III Studies Goserelin
• Box 5: Ongoing Phase III Studies Fulvestrant
• Box 6: Ongoing Phase III Studies Trastuzumab
• Box 7: Quick Facts - BMS-247550
• Box 8: Quick Facts - Temsirolimus
• Box 9: Quick Facts - SDX-105
• Box 10: Quick Facts - 4HPR
• Box 11: Quick Facts - Lapatinib
• Box 12: Quick Facts - Bevacizumab
• Box 13: Quick Facts - Theratope
• Box 14: Erlotinib
• Box 15: Gefitinib
• Box 16: Imatinib
• Box 17: Pemetrexed
• Box 18: NX473
• Box 19: Lonafarnib
• Box 20: Tipifarnib
• Box 21: Bortezomib
• Box 22: Arzoxifene
• Box 23: Patupilone
• Box 24: KOS-862

List of Tables

• Table 1: The Stage System
• Table 2: Risk Factors
• Table 3: List of Approved Drugs and Their Mechanisms of Action.
• Table 4: Hormonal Treatment Strategies
• Table 5: Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative Breast Cancer
• Table 6: Treatment Options for Women With Axillary Node-Positive Breast Cancer
• Table 7: Chemotherapy Drugs and Regimen
• Table 8: Summay of Drugs Involved in Breast Cancer Therapy
• Table 9: Short Facts Tamoxifen
• Table 10: Short Facts Anastrozole
• Table 11: Short Facts Letrozole
• Table 12: Short Facts Exemestane
• Table 13: Short Facts Goserelin
• Table 14: Short Facts Fulvestrant
• Table 15: Short Facts Trastuzumab
• Table 16: Cancer Immunotherapy Strategies
• Table 17: Progress on Ixabepilone
• Table 18: Progress on CCI-779
• Table 19: Progress on Fenretinide
• Table 20: Progress on Lapatinib
• Table 21: Progress on Bevacizumab
• Table 22: Progress on Theratope
• Table 23: Summary of Mid-Stage to Late stage Investigational Agents Under Development
• Table 24: Summary of Breast Cancer Early Stage Pipeline